It is no longer the current profile. Read the canonical profile and its correction notice.
We added a plain-language reader guide with cited answers, re-checked the generic octreotide label, and added Drugs@FDA approval records and two randomized acromegaly trials from our human evidence review. 1267
What this version reported
The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.↗↗↗
Reader guide in this version
Key takeaway
Octreotide is a lab-made peptide that mimics somatostatin, a hormone that suppresses growth hormone and several gut hormones. It was first approved in the United States as Sandostatin in 1988.1,2 It is FDA-approved to lower growth hormone and IGF-1 in acromegaly when other treatments have not worked or cannot be used, and to treat severe diarrhea and flushing from metastatic carcinoid tumors and watery diarrhea from VIP-secreting tumors.1 The label states that trials of this product did not show improvement in clinical signs and symptoms or a reduction in tumor size or growth rate.1
At a glance
- What it is
- A somatostatin analogue. The label states that it acts like natural somatostatin and is an even more potent inhibitor of growth hormone, glucagon and insulin.1
- FDA status
- FDA-approved. Drugs@FDA lists Sandostatin with an original approval date of October 21, 1988, and later octreotide products including Sandostatin LAR, Mycapssa and Bynfezia. The cited label has no boxed warning.1,2,3,4,5
- Human evidence
- Smaller randomized trials in acromegaly: a 14-day placebo-controlled study in 20 people and a Phase 3 trial in 92 adults.6,7
- Evidence strength
- Smaller controlled human trials
What is octreotide?
Octreotide is a lab-made peptide that the label says exerts actions similar to the natural hormone somatostatin.1
Drugs@FDA lists it as the active ingredient of Sandostatin (1988), Sandostatin LAR (1998), Mycapssa (2020) and Bynfezia (2024), among other octreotide applications. The label cited on this page is a generic octreotide label.1,2,3,4,5
How does octreotide work?
The label states that octreotide is an even more potent inhibitor of growth hormone, glucagon and insulin than somatostatin, and that it also reduces blood flow to the gut organs and the release of serotonin and several gut hormones.1
The label states that it substantially reduces growth hormone and IGF-1 levels in people with acromegaly.1
What do human studies show?
A 1990 double-blind, randomized trial assigned 20 people with acromegaly to octreotide or placebo for 14 days. Average growth hormone and IGF-1 levels fell significantly with octreotide, although two treated participants had no significant fall in growth hormone.6
In MPOWERED, 92 adults with acromegaly who had already responded to treatment were randomized to Mycapssa or to their previous somatostatin-analogue treatment. Biochemical response was maintained in 91% and 100% respectively, which met the trial’s prespecified non-inferiority criterion.7
These trials measured hormone levels in small or selected groups and cannot show long-term symptom control or uncommon harms.6,7
What the evidence base contains
- Controlled human trial A double-blind, randomized, placebo-controlled trial in 20 people with acromegaly, published in 1990, that measured growth hormone and IGF-1 over 14 days.6
- Controlled human trial MPOWERED: an open-label, randomized Phase 3 trial in 92 adults with acromegaly who had already responded to treatment, comparing a different octreotide product, Mycapssa, with the somatostatin-analogue treatment they had been receiving.7
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is octreotide FDA-approved?
Yes. Drugs@FDA lists Sandostatin, application NDA019667, with an original approval date of October 21, 1988, Sandostatin LAR on November 25, 1998, Mycapssa on June 26, 2020 and Bynfezia on September 27, 2024.2,3,4,5
The generic octreotide label cited here (DailyMed SPL version 2, published February 2, 2026) states that it is indicated to reduce growth hormone and IGF-1 in acromegaly when surgery, pituitary radiation and bromocriptine have not worked or cannot be used, to treat severe diarrhea and flushing from metastatic carcinoid tumors, and to treat watery diarrhea from VIP-secreting tumors.1
The label states that trials of this product did not show improvement in clinical signs and symptoms or a reduction in tumor size or growth rate, and that the trials were not designed to detect these effects.1
The label has no boxed warning. It states that octreotide is contraindicated in people sensitive to it, and its warnings cover heart rhythm and conduction problems, gallstones and their complications, high or low blood sugar, thyroid function changes, poor fat absorption and changes in vitamin B12 levels.1
Timeline
- FDA approves Sandostatin, according to Drugs@FDA.2
- Results of a placebo-controlled acromegaly trial of octreotide are published.6
- FDA approves Sandostatin LAR, according to Drugs@FDA.3
- FDA approves Mycapssa, according to Drugs@FDA.4
- FDA approves Bynfezia, according to Drugs@FDA.5
- DailyMed publishes the octreotide label version cited on this page.1
What is still unknown?
Whether this product improves symptoms or slows tumor growth, which the label says its trials were not designed to detect.1
How results for one octreotide product apply to another: MPOWERED studied Mycapssa, a different octreotide product from the one whose label is cited here.1,4,7
Sources for this version
- 1Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278 ↗
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 14, 2026
- 7Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026